Creating advanced CAR T cells from stem cells for better cancer treatment
Official title: Engineering detours around the biologic barriers to allogeneic, iPSC-derived CAR T immunotherapy
Funded at University of California Los Angeles · NIH-10854727 · Data updated 2026-11-12
This study is working on making CAR T cell therapy better for people with certain blood cancers by using special stem cells that can be modified to work more effectively, aiming to create a safer and more reliable treatment for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $43,796 |
| NIH project number | 5F30CA278297-02 |
| Project ID | NIH-10854727 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with hematological malignancies who may benefit from CAR T cell therapy.
✕Less likely to help
Patients with solid tumors or those who do not have hematological malignancies may not benefit from this research.
What this research studies
This research focuses on improving CAR T cell therapy, which has shown promise in treating certain blood cancers. The team aims to develop CAR T cells from allogeneic human pluripotent stem cells, which can be genetically modified to enhance their effectiveness. By addressing biological barriers that hinder the production of these cells, the researchers hope to create a more consistent and effective treatment option for patients. The approach includes innovative techniques to ensure the T cells develop properly and do not trigger adverse reactions in patients.
Why it matters
Potential benefit: If successful, this research could lead to more reliable and effective CAR T cell therapies for patients with difficult-to-treat cancers.
How similar studies have gone: Previous research has shown promise in using stem cells for CAR T cell therapy, but this specific approach is innovative and not widely tested.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Yoo, Sang Pil — University of California Los Angeles
- Study coordinator: Yoo, Sang Pil
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.